VCYT
Veracyte revenue up 15% to $151.8 million
Veracyte grew Q3 2026 revenue 15% to $151.8 million and announced a $100 million share repurchase program, highlighting strong profitability and operational cash flow.
VCYT news
Latest 3 stories · newest Nov 4, 2026
VCYT
Veracyte agrees to acquire Convergent Genomics
Veracyte, Inc. has entered into a definitive agreement and plan of merger with Convergent Genomics, Inc. that will result in the latter becoming a wholly-owned subsidiary following the transaction.
VCYT
Veracyte amends 2023 Equity Incentive Plan with 16.3M share reserve
Veracyte's Board amended its 2023 Equity Incentive Plan on June 10, 2026, reserving 16,306,156 shares for employee grants and incentives. The plan enables the company to attract and retain talent through equity compensation tied to future performance.
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same VCYT feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/VCYT/newsSTART FREE